Key points are not available for this paper at this time.
Abstract Environmental contamination by hexavalent chromium (Cr(VI)) and antibiotic drug residues pose significant challenges to public health and ecosystems. This study investigates the application of CoTiO 3 /BiVO 4 @MIL-Fe(53) (CT/BV@Fe-MOF) for the reduction of Cr(VI) and degradation of tetracycline (TCL) under visible light. After grafting an iron-based metal–organic framework MIL-Fe(53) on a modified CoTiO 3 /BiVO 4 composite, the photogenerated electrons could easily be transferred from CoTiO 3 to BiVO 4 /Fe-MOF species via interfacial charge transfer. UV–vis diffuse reflectance spectroscopy showed that charge carriers were formed in response to visible light absorption. The effect of different operating parameters, including catalyst load, pH, initial Cr(VI), and TCL concentration, was systematically evaluated during the photocatalytic process. The CT/BV@Fe-MOF composite exhibited 98.7% reduction efficiency in Cr(VI) (50 ppm) and 97.5% degradation efficiency towards TCL (30 ppm) within 90 min, resulting in a greater efficiency than the pristine CoTiO 3 , BiVO 4 , and Fe-MOF materials. The CT/BV@Fe-MOF composite displayed excellent stability over six cycles, highlighting its potential for practical applications. In addition, the plausible degradation pathway of TCL was evaluated using LC-ESI/MS analysis, while the TEST program was utilized to investigate the toxicity of the products generated during the degradation process.
Liu et al. (Sat,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: